Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotechnology sector.
The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.
2023 base-rate subscriptions are $A1,925 a year (including GST in Australia).
Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
Dr Boreham's Crucible: Imugene
US FDA Approves Cyclopharm Technegas - $280m A Year Market
Doherty Institute: Prof Sarah Gilbert Calls For 'Pandemic Preparedness'
US FDA Approves GSK Ojjaara (Cytopia's CYT387) For Myelofibrosis
Biotech Daily Editorial: It's A Long Way To The Top
Mesoblast Falls 58% On 2nd FDA CRL For Remestemcel-L For GvHD
Osteopore Appoints Robodebt Minister Michael Keenan Director
EBR: Wise Pivotal Heart Trial 'Efficacy, Safety'
Neuren Up 27% On FDA Acadia Daybue/Trifonetide For Rett Approval
November was a stellar month for the Biotech Daily Top 40 Index (BDI-40) and not too shabby for the ASX200, the three Big Caps, the Nasdaq Biotechnology Index (NBI) and even Cannabis Corner.
The BDI-40 climbed 20.85 percent in November, recovering to a collective market capitalization of $22,280 million.
The benchmark ASX200 was up 4.5 percent to 7,087 points, with the NBI up 4.9 percent to 3,874 points, while the collective market capitalization of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) recovered a very healthy 12.7 percent to $180,362 million.
Cochlear led the three Big Caps, up 13.3 percent to $17,885 million, followed by the CSL Magic Pudding back on the stove and up 12.9 percent to $126,674 million and Resmed up 11.7 percent to $35,803 million (see charts below).
Twenty-one of the Biotech Daily Top 40 Index (BDI-40) companies were up, 16 by more than 10 percent and two by more than 100 percent in one month (see below); with 15 down and just five falling more than 10 percent.
Imugene was the best (see yesterday’s Dr Boreham Crucible) up $480 million or 155.8 percent in November to $788 million, with 4D Medical up 105.6 percent to $331 million on US reimbursement and another FDA approval.
Opthea climbed 58.9 percent followed by Prescient (47.8%), Neuren (44.6%), Actinogen (42.1%), Next Science (32.1%), Clinuvel (22.2%), Impedimed (22.0%), Polynovo (19.1%), Pro Medicus (18.6%), Nanosonics (16.1%), Telix (15.2%), Mesoblast (14.2%), Avita (14.1%) and the now departed Kazia (11.8%).
Last month’s 216.7 percent best, Dimerix, led the falls, easing 23.7 percent to $58 million, followed by Nova Eye (22.9%), Alcidion (19.5%), Paradigm (18.5%) and Cynata (12.5%).
The current 11 companies in Cannabis Corner edged up 2.2 percent in November with three up, led by Botanix; two companies were unchanged and five were down, with Incannex departing (see below).
There are changes to the BDI-40 and other lists from today. Following the move of Kazia and Incannex to “the better valuations of the Nasdaq”, SDI has been promoted into the BDI-20, with Clarity and Curvebeam promoted to the Second 20. Patrys has become a day-traders delight and has been moved to the Third 20 due to its volatility.
Inhalerx and Little Green have joined Cannabis Corner, replacing Incannex and Melodiol (Creso).
Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Pharmaxis, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/